Cold agglutinin disease drug safety study ends early
Disease control
Terminated
This study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. It included 9 adults who had either taken the drug before or were new to it. The study was stopped early, an…
Phase: PHASE1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated May 07, 2026 18:42 UTC